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Expression of insulin-like growth factor binding protein-i mRNA in
human fetal kidney. Expression of insulin-like growth factor binding
protein-i (IGFBP-l) messenger RNA (mRNA) was studied in tissues of
human fetuses from 15 to 23 weeks of gestation. Northern blot analysis
revealed IGFBP-I mRNA in the fetal liver and kidney but not in other
fetal tissues, including the brain, heart, lung, skeletal muscle and
spleen. Studies by in situ hybridization histochemistry showed that, in
all fetal kidneys tested, the IGFBP-l mRNA was localized preferen-
tially to the epithelial cells of the collecting ducts, as well as to the cells
of developing glomeruli and in the subcapsular nephrogenic mesen-
chyme. Less intense labeling for IGFBP-I mRNA was seen in the
connective tissue stroma of the medullary pyramids. A weak signal was
detected in the mature glomeruli, and in the cells of the medullary
mesenchyme and capsular connective tissue. IGFBP-l protein was
detected by immunoperoxidase staining mostly around small blood
vessels but not in the respective endothelium. The protein was also
present in many epithelial cells of the collecting ducts and in stromal
connective tissue. These results show that the predominant sites of
IGFBP-1 transcription in the developing kidney are those with most
active differentiation.
Insulin-like growth factors (IGF-I and IGF-II) are ubiquitous
proteins in fetal as well as in adult tissues [1, 21. By immuno-
histochemical techniques IGFs are mainly localized to connec-
tive tissues or to cells of mesenchymal origin [3]. Although the
ontogeny and mechanisms of IGF action are largely unknown
[4], IGFs are considered important for the growth of fetal cells,
and for cellular differentiation. The multiple metabolic and
growth-stimulating actions of IGFs are differentially modulated
by specific IGF-binding proteins (IGFBPs) [5}. IGFBPs prolong
the half-lives of IGFs [6], serve as their carriers in the circula-
tion [7—9], and act as autocrine/paracrine regulators of the
biological actions of IGFs by regulating the availability of IGFs
to their cell surface receptors [10, 11]. Six different human
IGFBPs have been identified and their complementary DNAs
(cDNAs) have been cloned [12—21]. The IGFBPs differ regard-
ing their sites of synthesis and expression in tissues. In adult
tissues, IGFBP-l mRNA is expressed in liver, in primary liver
cancer cells, in secretory and decidualized endometrium and in
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ovarian granulosa cells [22], but not in proliferative endome-
trium, placenta, kidney or other tissues [14, 16]. In the human
fetus, IGFBP-1 has been found by immunohistochemistry in
several tissues [23]. However, the expression of different
IGFBPs in human fetal tissues and in specific tissue compart-
ments has not been thoroughly studied. This prompted us to
examine the expression of IGFBP-l mRNA as well as its
protein product in the fetal kidney.
Methods
Tissue specimens
After informed consent of the women and the approval of the
ethical committee of the Department of Obstetrics and Gyne-
cology, Helsinki University Central Hospital was obtained,
nine human fetuses of 15 to 23 weeks gestation were obtained
within approximately 45 minutes of prostaglandin-induced
abortions. The tissues were dissected, immediately frozen in
liquid nitrogen and stored at —70°C until processed for the
isolation of total RNA. For a positive control, endometrial
tissue was obtained from women undergoing hysterectomy for
uterine fibroids. Immediately after removal of the uterus, rep-
resentative samples were taken and frozen in liquid nitrogen.
Northern blotting
Each tissue including brain, heart, lung, skeletal muscle and
spleen was dissected from four fetuses aged 15 to 18 weeks, and
processed separately. Pieces of frozen tissues were homoge-
nized in guanidinium thiocyanate buffer, and RNA was isolated
using the method described by Chomczynski and Sacchi [24].
Total RNA was enriched for poly(A)-containing RNA by chro-
matography on oligo(dT)-cellulose columns [25]. For Northern
blot hybridization, 20 sg of total RNA and 3 jsg of poly(A)-
containing RNA from each fetal tissue was fractionated in 0.8%
agarose gel containing 1.6% formaldehyde and transferred onto
nitrocellulose filters. The filters were hybridized with a
labeled IGFBP-1 cDNA probe [16]. Labeling was carried out
using Multiprime DNA labeling system (Amersham Interna-
tional plc, UK). Autoradiography of the dried filters was
performed by exposing them to Kodak X OMAT AR film for
three days at —70°C.
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Table 1. Expression of IGFBP-1 mRNA in human fetal tissues
Abbreviations are: gw, gestation weeks; nt, not tested.
a Poly(A)-containing RNAb Total RNA
Protein
mRNA A B
Epithelial cells of the collecting ducts + + + +
Cells of the developing glomeruli + + — —
Subcapsular nephrogenic mesenchyme + + — —
Nephrogenic mesenchyme in the medulla (+) — —
Connective tissue stroma + + +
Mature glomeruli (+)
Around blood vessels — + -F + +
Kidney capsule + — +
In situ hybridization
In situ hybridization was performed on kidneys of five fetuses
from 15 to 23 weeks of gestation. Tissue sections, 4 m thick,
were cut on glass slides treated with 0.02% polylysine. Fixation
of the tissues was carried out in 3% paraformaldehyde for 10
minutes at 20°C. After washing twice in phosphate buffered
saline (PBS) the samples were treated with proteinase K (1
iWml) for 15 minutes at 37°C and rinsed with H20 and 0.1 M
triethanolamine, pH 8.0, containing 0.15 M NaCI. The slides
were then treated in 0.25% acetic anhydride in 0.1 M trietha-
nolamine buffer for 10 minutes at room temperature, washed in
a solution containing 0.3 M NaCI, 30 msi sodium citrate (2 X
SSC) and dehydrated in graded concentrations of ethanol
containing 0.3 M ammonium acetate. The slides were prehybrid-
ized in a solution containing 50% formamide, 0.6 M NaCl, 0.1 M
Tris-HCI, pH 8.0, 0.1 M dithiothreitol, 1 mii EDTA, 5 X
Denhardt's solution, 10% dextran sulfate, 0.1 mglml herring
sperm DNA and 0.5 mglml rRNA for two hours at room
temperature, dehydrated and air-dried. The 1500 nucleotides
long IGFBP-1 cRNA and mRNA equivalent strands were
Fig. 1. Northern blot hybridization analysis of human fetal tissues.
Poly(A)-RNA samples isolated from secretory endometrium (1), 18
week fetal liver (2), and 18 week fetal kidney (3) were fractionated on
agarose gel, transferred to nitrocellulose filter, and hybridized with
32P-labeled IGFBP-1 eDNA probe as described in Methods.
synthesized in the presence of 355-UTP as described previously
[26]. Hybridization was carried out in the same solution as
prehybridization with the RNA probe (2 to 3 x iocpm/.d). The
sense strand of IGFBP- 1 mRNA and a 900 nucleotide long
cRNA probe of placental protein 14 were used as a negative
control when interpreting hybridization patterns on tissue sec-
tions [26]. After hybridization, the slides were rinsed for 15
minutes at room temperature in 4 x SSC and in 2 x SSC, 30
minutes at 50°C in 1 x SSC containing 10 mri dithiothreitol and
1% Na-thiosulfate, and washed for two hours at 60°C in 0.1 x
SSC in 0.1% Na-thiosulfate. Tissue sections were then treated
with RNase-A (2 g/ml) for 15 minutes at room temperature and
washed twice in a solution containing 0.5 M NaCI, 10 mM
Tris-HC1, pH 8, and 1 mrvi EDTA. The final washes were in 0.1
x SSC in 1% Na-thiosulfate for two hours, first at 60°C and then
at room temperature. After a final dehydration the slides were
immersed in Kodak NTB-2 photographic emulsion, air-dried for
two hours and then exposed at 4°C for two to four weeks. The
slides were developed in Kodak D-19 solution, fixed, and
stained with hematoxylin.
Monoclonal antibodies
Monoclonal antibodies (F17-8D6 and Fl7-3E6) were pro-
duced as described [27]. Binding of the antibodies to IGFBP- 1
Fig. 2. In situ hybridization for the IGFBP-1 mRNA in the 23-week fetal kidney. Mayer's hemalum counterstain for nuclei, a. In the medullary area
strong labeling is seen in the collecting ducts (arrows), while some label is also present in the connective tissue stroma of the medullary pyramids
(small arrowheads). x300. b. High power view of a collecting duct showing a high density of grains over the epithelial cells (arrows) while some
grains are also evident on the cells of the nephrogenic mesenchyme (large arrowheads). x700. c. In the subcapsular glomerulogenic area, strong
labeling for the IGFBP-1 mRNA is seen in a zone of subcapsular nephrogenic mesenchyme and nascent glomeruli, but clearly less label is found
in the mature glomeruli and stroma localized subjacent to this zone. x 300. d. A mature glomerulus of the deep cortical area showing only a slight
concentration of grains. x700. e. In a high-power view of the subcapsular area, grains are seen in nascent glomeruli (arrows) suggesting that both
the visceral and parietal epithelium are labeled. Some label is also seen in cells of the kidney capsule (small arrowheads). x550. f. A control fetal
kidney of 23 weeks of gestation hybridized for the PP14 mRNA. In the subcapsular mesenchyme, only a few scattered grains are seen. No
concentration of grains is seen in nascent glomeruli (arrows). x550.
Tissue
Fetus 1a
15 gw
Fetus 2l
15 gw
Fetus 3°
16gw
Fetus 4a
18 gw
Liver + + nt +
Kidney — + +
Heart — — nt nt
Lung — — nt nt
Brain — — nt —
Muscle nt nt nt —
Spleen nt — nt nt
kb
2.3
2.0
0.5
Table 2. Cell types in the fetal kidney expressing IGFBP-l by in situ
hybridization and by immunohistochemistry using polyclonal (A) or
monoclonal (B) antibodies
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Fig. 3. Immunoperoxidase staining for the IGFBP-1 protein using polyclonal antibodies in the 23-week fetal kidney. Mayer's hemalum
counterstain. a. In the medullary area many cells of the collecting ducts show patchy positive reactions (arrows). x400. b. In the deep cortical area,
cross sections of the proximal parts of collecting ducts are stained in a similar patchy manner as in 2a (arrows). Also, strong staining is seen in the
outer aspect of blood vessels and in the connective tissue stroma surrounding them (large arrowheads) while the intimal side of the vessel wall is
negative. Mature glomeruli are negative (small arrowheads), x400. c. Control section of a similar area as in a was stained without the first antibody.
No immunoperoxidase reaction is seen in kidney tissues. x400. d. In the adult kidney, no staining for the IGFBP-l protein is seen in any part of
the tissue. x700,
was tested to see if they bind to the non-IGF-binding or
IGF-binding epitope of IGFBP-1. Monoclonal antibodies were
diluted to give 25% binding of 1251-IGFBP-1. The binding of
monoclonal antibodies to '251-IGFBP-l was displaced by
IGFBP-l (1 jig/mI) or by IGFBP-1 incubated with IGF-I (0.25 to
1.0 jig/mI) for one hour. Both monoclonal antibodies were
found to bind to the non-IGF-binding epitope of IGFBP-1,
because the results remained the same in the presence or
absence of added IGF-1.
Immunoperoxidase staining
Frozen section (4 jim) were cut from fetal kidney tissue of 23
weeks gestation. The sections were first exposed to 0,1%
hydrogen peroxide in 100% methanol to block endogenous
peroxidase activity. The immunostaining procedure was carried
out using the Vectastain ABC method (Vector Laboratories,
Burlingame, California, USA) as described previously [28].
Monoclonal antibodies and affinity-purified polyclonal rabbit
antibodies to IGFBP-1 [29] were used. The biotinylated anti-
mouse IgG (or anti-rabbit IgG for polyclonal antibodies) conju-
gate was diluted 1:300. Following these procedures, 3-amino-9-
ethylcarbazole (Sigma Chemical Co., St. Louis, Missouri,
USA) was used as a chromogen and 0.03% hydrogen peroxide
was applied to the sections. In control experiments the primary
antibody was omitted, or an unrelated first antibody was used.
Results
RNA from several tissues from four human fetuses of 15 and
18 weeks gestation was analyzed for the presence of IGFBP-1
mRNA by Northern blotting. These analyses showed a single
1.6 kb species of IGFBP-l mRNA in the liver. A band of a
similar size was seen in the secretory endometrium (positive
control). A corresponding mRNA species was also seen in the
kidney from 16- and 18-week-old fetuses but not from the
15-week-old fetuses (Fig. 1, Table 1). Fetal brain, heart, lung,
skeletal muscle and spleen did not show detectable mRNA.
In situ hybridization histochemistry was used to identify the
cell types in the fetal kidney expressing IGFBP-1 gene. In the
kidneys of all five fetuses, intense labeling for IGFBP-1 mRNA
was localized to the epithelial cells of the collecting ducts (Fig.
2, Table 2) as well as to the cells of developing glomeruli and to
the subcapsular zone of nephrogenic mesenchymal cells (Fig.
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2). Small amounts of IGFBP-l mRNA were also seen in the
connective tissue stroma of the medullary pyramids (Fig. 2).
Considerably weaker labeling was seen in the cells of mature
glomeruli, in undifferentiated mesenchymal cells of the medulla
and in the connective tissue of the renal capsule. In control
experiments using the sense strand of IGFBP-1 mRNA and the
PP14 cRNA probe, no labeling was detected (Fig. 2).
In immunoperoxidase staining of fetal kidney tissues for the
respective protein product, IGFBP-1 was seen preferentially in
the epithelial cells of the collecting ducts (Fig. 3, Table 2).
Immunoreactive IGFBP- 1 protein was also detected in many
areas of the connective tissue stroma of the kidney, particularly
around small blood vessels (Fig. 3). Staining for IGFBP-l using
monoclonal and polyclonal antibodies was similar in the
perivascular regions. Notably, however, the most luminal as-
pect of the vessels col-responding to the endothelial cells and
the smooth muscle layer of vascular walls were negative. Also,
the developing as well as the mature glomeruli were consis-
tently negative for the IGFBP-l.
Discussion
Brinkman and coworkers [14] have reported the expression
of IGFBP-l mRNA in fetal liver, but they did not find IGFBP-l
mRNA in fetal kidney. Using in situ hybridization we now show
the localization of IGFBP-1 mRNA in fetal kidneys between 15
and 23 weeks of gestation. Northern blot analysis verified the
expression of IGFBP-l mRNA in fetal kidney. The demonstra-
tion of IGFBP-l mRNA in the kidney from a 15-week-old fetus
by in situ hybridization, but not by Northern blot analysis
implies that the former method may be more sensitive than the
latter in detecting the IGFBP-1 mRNA signal. Transcription
was most remarkable in the epithelial cells of the collecting
ducts, in developing glomeruli (especially in the subcortical
most immature glomeruli), and in the subcapsular zone of
undifferentiated nephrogenic mesenchyme. IGFBP-l was local-
ized in epithelial cells of the collecting ducts indicating transla-
tion of IGFBP-1 in this section of the nephron. Recently, Hill
and coworkers demonstrated the presence of immunoreactive
IGFBP-l protein in several fetal tissues including the kidney
[23]. They found IGFBP-1 in both proximal and distal convo-
luted tubules, and to a lesser extent in the epithelial cells of
collecting ducts. Consistent with their results we found no
IGFBP-1 protein in the glomeruli, whereas a strong transcrip-
tion signal was noted in the immature cortical glomeruli. The
reason why IGFBP-l is not readily translated in these cells
remains unclear. We have seen a similar phenomenon in human
liver, where a strong labeling of IGFBP-1 mRNA was detected
in hepatocytes, and yet no protein was found (unpublished
data). In analogy with these findings IGFBP-3 is transcribed but
not translated in human MCF-7 breast cancer cells [30, 31]. The
IGFBP-1 mRNA and protein were co-localized in the stromal
connective tissues. No IGFBP-1 mRNA was found in the cells
surrounding small blood vessels, in which immunoreactive
IGFBP-l protein was clearly detected by both polyclonal and
monoclonal antibodies. We have observed a similar phenome-
non in 11 week decidua (unpublished data). Our results appear
to suggest that IGFBP-1 adheres to the perivascular connective
tissue while on transit through the blood vessel walls, or it may
subserve specific physiological functions in these cells.
Several lines of evidence suggest that IGF-I plays a physio-
logical role in the developing kidney. IGF-I receptors are found
in proximal tubular cells and in glomerular mesangial cells
[32—34]. In these sites, IGF-I stimulates DNA synthesis of
glomerular mesangial cells [33, 35—37]. Locally produced IGF-I
may have an important role for the function and growth of the
kidney [38, 391. Furthermore, subcutaneously infused IGF-I
increases creatinine clearance and glomerular filtration rate in
adults [40]. IGFBP-l either stimulates or inhibits the local
actions of IGFs [27, 41, 42], but so far the mode of IGFBP-l
action in the fetal kidney is not known.
The functional maturation of the fetal kidney is a long process
and extends into several months of postnatal life. Differentia-
tion of the nephrogenic mesenchyme begins during the seventh
week of gestation, and one third of the nephrons have devel-
oped by 20 weeks of gestation. The predominant sites of
IGFBP-l mRNA expression in the kidney represent sites of
most active differentiation of developing kidney cells, that is,
the collecting ducts and immature glomeruli.
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